innovative therapeutics

Clicks: 320
ID: 186145
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #6 of 42 articles by views in journal of nuclear materials

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.
Reference Key
phd2016jacc:innovative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Laura M.G. Meems, MD, PhD;John C. Burnett, Jr., MD
Journal journal of nuclear materials
Year 2016
DOI
10.1016/j.jacbts.2016.10.001
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.